Titan Biotech reported a significant improvement in profitability for the first quarter of FY26, with standalone net profit rising 53% year-on-year to ₹94.6 crore. The growth was supported by a 29% increase in revenue, which reached ₹609.8 crore compared to ₹472.2 crore in the corresponding period last year. Consolidated net profit also expanded by 58% to ₹108.6 crore, up from ₹68.6 crore in Q1FY25.

The company’s operating performance strengthened alongside top-line growth. Standalone earnings before tax (EBT) climbed to ₹127.3 crore from ₹81.1 crore, reflecting an expansion in operating leverage. The Board of Directors approved the unaudited financial results at its meeting held on August 13, 2026. The results have been reviewed by the Audit Committee and subjected to a limited review by the statutory auditors as per SEBI regulations.

Financial Highlights

Consolidated Performance

On a consolidated basis, total income from operations stood at ₹609.8 crore, identical to the standalone figure. Consolidated net profit after tax was ₹108.6 crore, compared to ₹68.6 crore in the prior year period. Basic earnings per share for the consolidated entity were ₹2.63, up from ₹8.30 in Q1FY25, though the face value difference (₹10 vs ₹2 in prior reporting) requires careful comparison. The paid-up equity share capital remained unchanged at ₹82.6 crore.

What the Numbers Show

The divergence between revenue growth (29%) and earnings before tax growth (57%) indicates improved operational efficiency during the quarter. The expansion in pre-tax profits suggests that cost controls or product mix shifts allowed the company to retain more earnings per unit of sales than in the previous year. This operational improvement translated directly to the bottom line, where both standalone and consolidated net profits outpaced revenue growth significantly. The company noted that freight amounts were added to revenue from operations and neutralized in total other expenses, ensuring no distortion in sales figures.

Titan Biotech Ltd has closed its trading window for all designated persons effective Wednesday, July 1, 2026. The window will remain shut until 48 hours after the company declares its unaudited financial results for the quarter ended June 30, 2026. This measure is implemented to comply with the SEBI (Prohibition of Insider Trading) Regulations, 2015, and the company's internal code of conduct for preventing insider trading.

The restriction covers securities of the company and applies to all directors, promoters, key managerial personnel (KMPs), other designated persons, employees, and their immediate relatives. The closure ensures that no insider trading occurs while the financial results for Q1FY26 are being finalized and prepared for public disclosure.

The company stated that the specific date for the board meeting to declare the unaudited financial results for the quarter ended June 30, 2026, will be intimated in due course. Once the results are announced to the stock exchange and made public, the trading window will reopen 48 hours later.

The communication was addressed to the Corporate Services Department of BSE Ltd. The filing was signed by Charanjit Singh, Company Secretary and Compliance Officer of Titan Biotech Ltd, on June 23, 2026.